The chemical and pharmaceutical industry in China: Opportunities and threats for foreign companies

The Chemical and Pharmaceutical Industry in China: Opportunities and Threats for Foreign Companies

Volumn , Issue , 2005, Pages 1-295

  Festel, Gunter ^a   Kreimeyer, Andreas ^b   Oels, Udo ^c   Von Zedtwitz, Max ^d  

^a Vorstand BASF Aktiengesellschaft ^*  (Switzerland)

^b BASF SE   (Germany)

^c BAYER AG   (Germany)

^d Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892137656     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/b137786     Document Type: Book

References (96)

1. Abelshauser W, von Hippel W, Johnson JA, Stokes RG (2004) German Industry and Global Enterprise, BASF: The History of a Company, Cambridge University Press, Cambridge
2. Arora A, Landau R, Rosenberg N (1998) Chemicals and Long Term Economic Growth. Wiley
3. Arnold HM, Lamottke K (2003) Erfolg im Abwärtszyklus - Geschäftsmodelle, die vom schwierigen wirtschaftlichen Umfeld profitieren können. Sonderausgabe Biotechnologie, GoingPublic Verlag, pp 122-123
4. Asia Pulse Businesswire (2004) Electronic Material Industry and Market in China. August 11, 2004
5. BASF Aktiengesellschaft (1994) BASF: Milestones in its History
6. BASF and Chinese Academy of Engineering (2002) Proceedings on Symposium on Energy, Environment, Sustainable Development
7. Becker J (2000) The Chinese. John Murray, London
8. Beckmann (2004) China: Die aufstrebende Wirtschaftsmacht. Deutsche Bank Global Markets Research, Frankfurt
9. Business Daily Update (2004a) China's Computer Chip Market Hits US$24, 99b in 2003. February 23, 2004
10. Business Daily Update (2004b) Semiconductor Industry to Get Boost in China. March 22, 2004: p 22
11. Chang-Xiao Liu, Pei-Gen Xiao (2002) Recalling the research and development of new drugs originating from Chinese traditional and herbal drugs. Asian Journal of Drug Metabolism and Pharmacokinetics 2:133-156
12. Chemical Engineering News (2002) Electronic Chemicals. July 15, 2002: p 19
13. Chemical Week (2003) Electronic Chemicals. June 23, 2003
14. Chen S (2003) Comparative Study on Pharmaceutical Industries between China and India. In: China Pharmaceutical Daily, July 2 (in Chinese)
15. Chen W (2004) Looking For an Industry Cure. China International Business, Issue 204, November 2004, pp 34-37
16. China Daily (2003) Internet edition, November 12, 2003
17. China Economic Information Network (2003) China's Pharmaceutical Industry 2003. Beijing
18. China Post (2004) China 300-mm wafer plant to open. September 15, 2004
19. rd
20. Cochran S (2000) Encountering Chinese Networks: Western, Japanese, and Chinese Corporations in China, 1880-1937. University of California Press, Berkeley
21. Cohen MS (1984) The Great Cephalosporin Wars. European Journal of Clinical Microbiology 3:177-179
22. Cooke M (2003) Diverse views on the future. European Semiconductor, April 2003:25-30
23. Davenport RE, Fink U, Yoshio I (2004) Electronic Chemicals. SRI Consulting
24. Dow Jones News Services (2004) Chinas Chipmaker Market Will Be $100 Billion by 2008. February 16, 2004
25. Downton C, Clark I (2003) Statins - the heart of the matter. Nature Reviews Drug Discovery 2, pp 343-344
26. Easton R (2003) Supply Chain Management in China: Assessments and Direction. Ascet Volume 5
27. Electronic Engineering Times (2003) October 27, 2003
28. Electronic News (2004a) IC demand on the Rise in China. March 29, 2004
29. Electronic News (2004b) China denies overcapacity, unfair trade allegations. March 22, 2004
30. Enriquez J, Goldberg R (2000) Transforming Life, Transforming Business: The Lifescience Revolution. Harvard Business Review, March-April, 96-104
31. Espicom Business Intelligence (2004) China Market Study. West Sussex
32. st 2002
33. Festel G (2003a) Historical Evolution and Actual Trends of the Global Chemical Industry. Chemie & Wirtschaft, Jg. 2, Ausgabe 1, Februar 2003, 27-34
34. Festel G (2003b) Shareholder Value as Driving Force for Transformations of Chemical Companies. Chemie & Wirtschaft, Jg. 2, Ausgabe 4, November 2003, 26-42
35. Festel G, Knöll J, Götz H, Zinke H (2004) Bio-ways to drugs. European Chemical News. 19-25 January 2004, 22
36. Financial Times UK (2004a) Speedy Rise of China's Top Chip. November 2, 2004: p 29
37. Financial Times UK (2004b) Fear of High-tech Piracy Makes some Microchip Companies Cool about China. July 15, 2004: p 11
38. Forney M (2003) China's Failing Health System. Time Asia, Beijing
39. Fukuyama F (1995) Trust. Hamish Hamilton
40. Frankfurter Allgemeine Zeitung (2004) Taiwanesische Unternehmen locken Infineon. March 23, 2004: p 24
41. Geng Y, Côté R (2001) EMS as an Opportunity for Enhancing China's Economic Development Zones: the Case of Dalian. In: Environmental Management for Industrial Estates-A Resource & Training Kit. UNEP Division of Technology, Industry and Economics, Production and Consumption Branch, Paris
42. Geng Y, Côté R (2003) Environmental Management System at the Industrial Park Level. Environmental Management, Vol. 31, No. 6, 784-794
43. Global Sources (2004) Consumer Electronic Outlook (see also: www.globalsources.com)
44. Guo D (2003) How Overseas Companies Invest into China's Pharmaceutical Market. www.healthoo.com (in Chinese)
45. Haug C, Lamottke K (2004) Pionierarbeit - auch in der Mitarbeiterführung. ChinaContact, 1+2, pp 29-40
46. Hein C (2004) Warnschuss aus China. Frankfurter Allgemeine Zeitung 290: p 11
47. Henderson GE et al. (1998) Trends in Health Services Utilization in Eight Provinces in China, 1989-1993. Social Science and Medicine. 47(12):1957-1971
48. IMS Health (2004) Market prognosis China 2004-2008. London
49. Jackson R, Howe N (2004) The graying of the middle kingdom. Center for Strategic and International Studies, Research publication, April 2004
50. Joseph G and Schaefer R (2004) China: Auf dem Weg zur Wirtschaftsgroßmacht. Economic Research Allianz Group Dresdner Bank Working Paper, Frankfurt
51. Jungmittag A, Reger G, Reiss T (eds.) (2000) Changing Innovation in the Pharmaceutical Industry - Globalization and New Ways of Drug Development. Berlin, New York et al.
52. th, 2003
53. Langlois JD (2001) The WTO and China's Financial System. China Quarterly, Vol. 167, 610-629
54. Liao J (2003) The Development Route of Western Pharmaceutical Enterprises. www.mediaChina.net (in Chinese)
55. Liu S and MacKellar L (2001) Key Issues of Aging and Social Security in China. International Institute for Applied Systems Analysis, Laxenburg
56. Liu Y, Rao K and Hsiao WC (2003) Medical Expenditure and Rural Impoverishment in China. Centre for Health and Population Research, Harvard University, Boston
57. MacKinnon R (2004) Kaliumkanäle und die atomare Basis der selektiven Ionenleitung (Nobel-Vortrag). Angew. Chem. 116, 4363-4376
58. Mandell GL, Douglas RG, Bennett JE (1990) Principles and Practice of Infectious Diseases. Churchill Livingstone, New York
59. Moore G (1997) An Update on Moore's Law. Intel Developer Forum, Keynote. San Francisco. Sep. 30, 1997
60. Newman DJ, Cragg GM, Snader KM (2003) Natural Products as Sources of New Drugs over the Period 1981-2002. J. Nat. Prod. 66, 1022-1037
61. News Report (2003) How to handle upcoming wave of large volume of pharmaceutical patents to be terminated. In: China Industrial Commerce Daily, February 2003 (in Chinese)
62. Porter ME (1980) Competitive Strategy. Free Press, New York
63. Prahalad CK and Lieberthal K (1998) The End of Corporate Imperialism. Harvard Business Review, Boston
64. RDSL Asia (2004) China - Chip Industry Sees Growth in Production, Investment. February 17, 2004
65. Reddings G (1993) The Spirit of Chinese Capitalism. De Gruyter
66. Reed Electronics (2004) www.reed-electronics.com/semiconductor/contents/ pdf/SIBreakfast2004.pdf
67. San Jose Mercury News (2004a) China, Partner to U. S. Tech Firms, is also a Fast-growing Thread. March 14, 2004: p 1
68. San Jose Mercury News (2004b) U. S. High-Tech Giants Invest in Future Competitor. March 15, 2004
69. Schmitt S (2002) der Arzneimittelmarkt der VR China. German-Chinese Business Forum 02/2002:7-12
70. Schmitt S (2002a) Arzneimittelvertrieb - VR China lässt ausländische Unternehmen zu. German-Chinese Business Forum 02/2002:28-30
71. Sharper I (2002) All change for Chinese pharma. Scrip Magazine 12/02:6-7
72. South China Morning Post (2004a) SMIC Sales to Grow on Increased Capacity. February 14, 2004: p 4
73. South China Morning Post (2004b) Chipmakers Risk Capacity Oversupply. March 24, 2004: p 2
74. Special Report (2004a) Strategies of Multinational Pharmaceutical Companies in China. www.hc360.cn (in Chinese)
75. Special Report (2004b) Development Analysis on China's FDI Firms in Pharmaceutical Industry behind the Trend of Globalization. www.jinhf.com (in Chinese)
76. Taiwan Economic News (2004) SMIC to unveil mainland China's first 300mm wafer fab soon. September 20, 2004
77. The Guardian (2003) Dismal fate awaits China's millionaires. October 31, 2003
78. Time Magazine (2004) August 9, 2004: p 13
79. Torreblanca M (2004) The China syndrome. Scrip Magazine 04/04:28-29
80. Trinh T (2004) Deutsche Investitionen in China - Chance für deutsche Unternehmen? Deutsche Bank Research, Frankfurt
81. United Nations Environment Programme (UNEP) (2001) Environmental Management in Industrial Estates in China. Paris, France: United Nations Environment Programme, Division of Technology, Industry and Economics. p 95
82. Vaishampayan P and Chen VY (2004) Will India and China dominate pharmaceutical manufacturing? UBS Investment Research - Q-Series: Asian Pharma Sector
83. Venture Capital Journal (2004) Road to Riches? June 1, 2004
84. Vernon R (1966) International Investments and International Trade in the Product Life Cycle. In: Quarterly Journal of Economics, May 1966, pp 190-207
85. th edition, Englewood Cliffs, NJ; Prentice Hall
86. Von der Hagen W, Gruss A and Wolff B (2002) Das Wachstumspotenzial im Gesundheitswesen in China. German-Chinese Business Forum 02/2002:23-27
87. Wang X (2002) Impact on the Chinese Pharmaceutical Industry after Entering into the WTO. In: China Chemical Engineering Information, July 2002 (in Chinese)
88. Watanabe M (2002) Holding company risk in China: a final step of state-owned enterprises reform and an emerging problem of corporate governance. China Economic Review, December 2002, Vol. 13, No. 4, 373-381 (9)
89. Webber DE (2003a) Accelerating Innovative Pharmaceutical Research and Development in China: A Case Study. International Federation of Pharmaceutical Manufacturers Associations, Geneva Switzerland
90. Webber DE (2003b) Encouraging Pharmaceutical R&D in Developing Countries. International Federation of Pharmaceutical Manufacturers Associations, Geneva Switzerland
91. White RS (1998) Technological Systems and Organizational Change: China's Pharmaceutical Industry in Transition. Ph. D. Dissertation, Sloan School of Management, Massachusetts Institute of Technology
92. WHO (The World Health Organisation) (2002) Traditional Medicine - Growing Needs and Potential. WHO Policy Perspectives on Medicines. No. 2 May 2002. WHO, Geneva Switzerland
93. World Bank (1997) China 2020: Financing Health Care: Issues and Options for China
94. Yang JT (2001). The Environmental Management of Industrial Estates in China: Issues and Perspectives. Paper presented at the Environmental Management of Industrial Estates Workshop, 8-11 July, Dalian, China
95. Yang X (2004) Developing Fine Chemical Industry within Chemical Parks in China. China Petroleum and Chemical Industry, No. 3, 62-65
96. Zheng X (2004) Implementation of Classified Drug Administration System Gives Full Play to Self-medication in Health Care. Proceedings of the World Self-Medication Industry 6th Asia Pacific Conference, Beijing China, October 2004. In press